Pharma/Biotech News
Subscribe to Pharma/Biotech News

The Lead

Novartis Presents New Data on 21 Medicines, 11 Investigational Compounds at ASCO, EHA

May 28, 2015 12:01 pm | News | Comments

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.  Read more...

EMA Validates Gilead's Marketing Application for HIV Treatment

May 28, 2015 9:26 am | News | Comments

Review of the MAA will be conducted by the EMA under the centralized procedure, which, when...

Salix Announces FDA Approval of IBS-D Treatment

May 28, 2015 9:20 am | News | Comments

The FDA approval was based on data from three clinical studies of more than 3,000 patients. Read...

NIH: Major Study Finds Earlier HIV Treatment Improves Health

May 28, 2015 9:13 am | by Lauran Neergard, AP Medical Writer | News | Comments

The findings are preliminary, but the NIH found them so compelling that it stopped the study a...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Par Specialty Pharmaceuticals Launches Cortisporin-TC Otic Suspension

May 27, 2015 2:16 pm | News | Comments

Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., today announced the launch of Cortisporin®-TC Otic Suspension (colistin sulfate - neomycin sulfate - thonzonium bromide - hydrocortisone acetate otic suspension). Read more..

FDA Approves Boehringer Ingelheim's COPD Inhalation Spray

May 27, 2015 1:53 pm | News | Comments

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray. Read more...

Novartis, Rani Therapeutics Collaborate on Drug Delivery

May 27, 2015 1:46 pm | News | Comments

Rani Therapeutics announced today that it has entered into a collaboration with Novartis to evaluate Rani's novel oral biotherapeutics drug delivery platform. The companies have agreed to begin feasibility studies to evaluate how selected Novartis' proprietary biologics can be delivered into the bloodstream using Rani's unique route of administration. Read more...


Genetically Modified Herpes Virus to Treat Skin Cancer

May 27, 2015 1:13 pm | by Stephanie Guzowski, Editor | News | Comments

An experimental treatment using a genetically modified strain of the herpes simplex 1 virus has been shown to be effective in killing skin cancer cells and halting tumor growth, according to new research. The oncolytic virus immunotherapy, called T-VEC, was used to treat patients with melanoma in a Phase 3 clinical trial. Read more...

Sanofi, Regeneron Annouce Positive Phase 3 Data for Arthritis Drug

May 27, 2015 9:26 am | News | Comments

No unexpected safety findings were observed.

AbbVie Presents Phase 3 Data in Japan from Hepatitis C Treatment Study

May 27, 2015 9:01 am | News | Comments

Across all study arms, three patients discontinued treatment due to adverse events. Read more...

Amgen Terminates Co-Development of Brodalumab with AstraZeneca

May 26, 2015 1:16 pm | by Stephanie Guzowski, Editor | News | Comments

Amgen ended its co-development of brodalumab with AstraZeneca after some patients who took the experimental psoriasis drug experienced suicidal thoughts or behavior, which Amgen believes would likely require restrictive labeling. Read more...

Peeking into Healthy Brains to See If Alzheimer's is Brewing

May 26, 2015 10:34 am | by Lauren Neergaard, AP Medical writer - Associated Press | News | Comments

Now researchers are adding tau brain scans to an ambitious study that's testing if an experimental drug might help healthy but at-risk people stave off Alzheimer's. Whether that medication works or not, it's the first drug study where scientists can track how both of Alzheimer's signature markers begin building up in older adults before memory ever slips. Read more...


Cellular Biomedicine Reports Positive Phase 1 Study Results for T-Cell Therapy

May 26, 2015 8:11 am | News | Comments

The results of this trial to date demonstrated that five out of seven patients responded to the treatment. CD30-directed CAR-T cell therapy was demonstrated in this trial to be safe, feasible and efficient. Read more...

Takeda Announces Seasonal Flu Vaccine Sales Agreement with Kaketsuken in Japan

May 26, 2015 7:57 am | News | Comments

Given the aging population in Japan, the demand for seasonal influenza vaccine is increasing. Read more...

Freshly Squeezed Vaccines

May 22, 2015 8:39 am | by MIT | News | Comments

Researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system’s B cells. Read more...

Janssen, Achillion Pharmaceuticals Team Up to Fight Hepatitis C

May 22, 2015 8:24 am | News | Comments

A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. Read more...

CVS Paying $10.4B in Cash for Drug Distributor Omnicare

May 22, 2015 8:23 am | by Tom Murphy, AP Business Writer | News | Comments

CVS Health will pay more than $10 billion for pharmaceutical distributor Omnicare in a deal primed to feed its fast-growing specialty drug business and tap a lucrative and growing market: care for the elderly. Read more...


New Data on Boehringer Ingelheim's COPD Treatment

May 21, 2015 1:30 pm | News | Comments

Boehringer Ingelheim announced new data analyses from the pivotal Phase III TONADO 1&2 studies (NCT01431274/NCT01431287), which explored the efficacy and safety of investigational tiotropium/olodaterol delivered via the Respimat inhaler for chronic obstructive pulmonary disease (COPD) compared to the individual components (tiotropium and olodaterol delivered by the RESPIMAT inhaler) alone. Read more...

Novartis Announces COPD Phase 3 Results

May 21, 2015 1:23 pm | News | Comments

Today, Novartis announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149 (indacaterol/glycopyrronium) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Read more...

Emmes Announces FDA Clearance of New Medical Device

May 21, 2015 1:18 pm | News | Comments

The Emmes Corporation today announced that the U.S. Food and Drug Administration (FDA) has given marketing clearance for a new device that allows doctors to more accurately assess children's weight without the use of a weight scale. Weight estimates are used in emergency situations and in developing countries where scales may not be available. Read more...

Actavis Launches New Alzheimer's Disease Therapy

May 21, 2015 9:30 am | News | Comments

The drug was approved by the U.S. Food and Drug Administration (FDA) in December for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Read more...

FDA Approves First and Only Four-Times-A-Year Schizophrenia Treatment

May 20, 2015 12:44 pm | News | Comments

There's a new treatment option for schizophrenia – Invega Trinza (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered just four times a year, providing the longest dosing interval available. Read more...

Johnson & Johnson Expects Lucrative Return on Drug Pipeline

May 20, 2015 12:35 pm | by Associated Press | News | Comments

Johnson & Johnson expects a lucrative return from its pharmaceutical business, with plans to seek approval by 2019 for more than 10 new products, each with the potential to top $1 billion in annual sales. Read more...

Activists Want to Void Patents on Gilead's High-Priced Hepatitis C Drug

May 20, 2015 12:15 pm | by Ryan Bushey, Associate Editor | Articles | Comments

These patents are being challenged all over the world. Read more...

Promising Malaria and Dengue Vaccines Will Not Defeat Diseases

May 20, 2015 8:54 am | by Christopher J. Pace, Ph.D., GlobalData Managing Analyst, Infectious Diseases | Articles | Comments

Some industry pundits rightfully question the modest protective efficacies of CYD-TDV and RTS,S/AS01. Read more...

Sanofi, Regeneron Announce Positive Phase 2 Data for Asthma Drug

May 20, 2015 8:42 am | News | Comments

Based on discussions with the U.S. Food and Drug Administration (FDA), this Phase 2b study may be considered one of two pivotal efficacy studies required for a potential dupilumab biologics license application (BLA) in asthma. Read more...  

Australian Researcher Helps with Ebola Vaccine Trials

May 20, 2015 8:41 am | by Monash University | News | Comments

An Australian researcher has helped identify the kind of human trial that is most effective for testing Ebola vaccines. Read more...

HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma

May 19, 2015 12:36 pm | News | Comments

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited under which Mayne Pharma will invest $2.5 million in HPPI in a private common stock and warrant financing.  Read more...

Inner-City Asthma Care Program Reduces Student Absenteeism by Up to 20 Percent, Shows Study

May 19, 2015 12:00 pm | News | Comments

New data from a school asthma management program, “Building Bridges for Asthma Care,” presented today at the American Thoracic Society 2015 International Conference, show a significant decrease in school absenteeism among children with asthma from inner-city schools who were enrolled in the program. Read more...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.